Infectious Diseases – Products

Oxford Nanopore, and Day Zero Diagnostics (DZD), announced a collaboration to develop an end-to-end solution for the diagnosis of bloodstream infections, a leading cause of sepsis.

The mechanism targets both integrated virus and cccDNA; expected to begin clinical testing by end of 2024. Preclinical program data to be presented at the 2023 Hep DART Conference .

A multitude of resistance genes in crop genomes could be brought back to life.

Visitors to London Vet Show can see how new reagent pack sizes make rapid point-of-care PCR more accessible.

Glox Therapeutics, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.

Armis Biopharma, Inc. announced that the company received a $20.3 million contract from the Defense Threat Reduction Agency (DTRA) to develop its proprietary Veriox® DECON chemical warfare agent (CWA) decontamination product.

The partners will offer an integrated sample-to-report rapid nanopore sequencing analysis platform for neonatal/paediatric intensive care units to support clinicians in acute settings.

CEO Gordon Sanghera discusses how Apple’s latest product announcement means complex processing required for DNA/RNA sequencing can now be run from the latest MacBook Pro™ or iMac ™.

Because RSV, influenza, and COVID-19 share symptoms, accurate testing is needed to distinguish one from the other. The CE-IVD marked multiplex TaqPath COVID-19, Flu A/B, RSV Combo Kit is specifically designed to detect and differentiate between these three viruses during flu season

Oxford Nanopore Technologies, announce that bioMérieux is making an immediate £70M investment in Oxford Nanopore.